Search Back New search Go to resultsDiseaseMain groupCross-Sectional, Transplantation, Cellular TherapySolid TumorsProtocol groupGastroenterologic OncologyGynecological OncologyVisceral SurgeryDiseasePeritoneal Carcinomatosis, SecondaryPseudomyxoma PeritoneiSubgroupICD10C78.6MeSHPseudomyxoma PeritoneiSequenceChemotherapyChemo-substanceMitomycinChemo-substanceMitomycinChemo-substanceMitomycinChemo-substanceMitomycinNo. Substances1 RadiotherapySupportive therapySupportive substanceBalanced Crystalloid SolutionDexamethasoneNaCl 0.9%Supportive substanceBalanced Crystalloid SolutionDexamethasoneNaCl 0.9%Supportive substanceBalanced Crystalloid SolutionDexamethasoneNaCl 0.9%Supportive substanceBalanced Crystalloid SolutionDexamethasoneNaCl 0.9%No. Substances3Protocol classificationTherapy classificationcurrent standardIntensityStandard doseTherapy indicationTherapy phaseTherapy intentionpalliativeRisksBleedingEmetogenicity (MASCC/ESMO)FistulasInfections only studiesPublicationAuthorKuijpers ADiseasePeritonealkarzinom durch kolorektales Ca oder Pseudomyxoma peritonii, operabel, T1-T4, Stadium I-IVOriginDepartment of Surgical Oncology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, AmsterdamProtocols in Revision 1 protocol foundProtocols under revision.HIPEC - Mitomycin 35, Peritoneal Carcinomatosis, Secondary (PID123 V1.0)
